Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 7/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.31 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25688777 | 0.96 | SLC29A1 (0.36) | SLC29A1TP53CYP3A4HIF1AABCC4 | |
| SCHEMBL25688747 | 0.94 | TYMP (0.32) | SLC29A1 | |
| SCHEMBL25688776 | 0.89 | TYMP (0.32) | SLC29A1 | |
| SCHEMBL24321999 | 0.86 | SLC29A1 (0.37) | SLC29A1ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL25688735 | 0.85 | TYMP (0.32) | SLC29A1 | |
| SCHEMBL18917301 | 0.84 | P2RY12 (0.39) | ADORA1P2RY12 | |
| SCHEMBL18927171 | 0.84 | P2RY12 (0.39) | ADORA1P2RY12 | |
| SCHEMBL24321953 | 0.82 | SLC29A1 (0.38) | SLC29A1ADORA1ADORA3ADORA2AADORA2B | |
| SCHEMBL20547951 | 0.81 | P2RY12 (0.35) | ADORA1P2RY12 | |
| SCHEMBL18917302 | 0.81 | KDM4E (0.37) | ADORA1P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11660311-B2 | Cyclic dinucleotides as anticancer agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11660311-B2 | Cyclic dinucleotides as anticancer agents | DPYD, CD38, DUT | SLC29A1 367/4885TP53 131/4885CYP3A4 3042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.